Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
A randomized, open-label, three-period, three-sequence, multiple dosing crossover, phase 1 clinical trial to evaluate the effect of DWP14012 on the pharmacokinetics of DWC202201 after co-administration of DWP14012 and DWC202201 in healthy subjects

Official Title
-----------------
A Randomized, Open-label, Three-period, Three-sequence, Multiple Dosing Crossover, Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 After Co-administration of DWP14012 and DWC202201 in Healthy Subjects

Conditions
-----------------
Drug Drug Interaction

Intervention / Treatment
-----------------
* Drug: DWP14012
* Drug: DWC202201


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy adults aged ≥ 19 and ≤ 50 years at screening Subjects with a body weight ≥ 50.0 kg to ≤ 90.0 kg with a body mass index (BMI) of ≥ 18.0 kg/m2 to ≤ 27.0 kg/m2 at screening ※ BMI (kg/m2) = body weight (kg)/[height (m)]2 Subjects who voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a sufficient explanation on this study and fully understanding the information Subjects who are eligible to participate in the study at the discretion of the investigator by physical examination, laboratory tests, and investigator questioning, etc. Exclusion Criteria: Subjects with a disease or a history related to hepatobiliary system, kidney(severe kidney disorder ect.), nervous system, respiratory system, digestive system, endocrine system, hematology system, circulatory system(Heart failure, Torsades de pointes ect.), unrinary system, psychiatry ect. Subjects with digestive disease(gastrointestinal ulcers, gastritis, stomach cramps, gastroesophageal disease, Crohn's disease) or history of surgery(except appendectomy, hernia surgery) which can affect on saftey and pharmacodynamics Subjects with hypersensitivity or history of clinically significant hypersensitivity to drugs including potassium competitive acid blocker [P-CAB] class, aspirin, antibiotics, etc. Subjects with hereditary disorders including galactose intolerance, Lapp lactase deficiency, glucose-galactose malabsorption, etc. Subjects with history of inherited muscle disorders Subjects with a history of drug abuse or a positive result of using abusive drugs in the urine drug screen Subjects who participated in other clinical trials (including bioequivalence studies) within 6 months prior to the first scheduled dose of the IP Subjects who donated whole blood within 2 months, donated blood components within 1 month, or received blood transfusion within 1 month prior to the first scheduled dose Subjects who are unable to refrain from grapefruit-containing products from 3 days prior to the first scheduled dose until last discharge from hospital Subjects or their spouses or partners who are unable to use medically acceptable appropriate double-method of contraception or medically acceptable contraception throughout the study period and for at least 4 weeks after the last IP administration Subjects who are unable to refrain from smoking(>10pieces/day) from 3 days prior to the first scheduled dose until last discharge from hospital Subjects with alchoholic disorders or subjects who are unable to refrain from drinking(>21units/week) from 3 days prior to the first scheduled dose until last discharge from hospital Subjects who are unable to refrain from caffein(>5units/day) from 3 days prior to the first scheduled dose until last discharge from hospital

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Cohort 1<br>Treatment A: DWC202201 40 mg qd for 7 days Treatment B: DWP14012 40 mg qd for 7 days, followed by DWC202201 40 mg qd + DWP14012 40 mg qd for 7 days Treatment C: DWP14012 40 mg qd for 14 days | Drug: DWP14012<br>* Potassium-competitive acid blocker<br>Drug: DWC202201<br>* Atorvastatin Calcium Trihydrate<br>|
| Experimental: Cohort 2<br>Treatment C: DWP14012 40 mg qd for 14 days Treatment A: DWC202201 40 mg qd for 7 days Treatment B: DWP14012 40 mg qd for 7 days, followed by DWC202201 40 mg qd + DWP14012 40 mg qd for 7 days | Drug: DWP14012<br>* Potassium-competitive acid blocker<br>Drug: DWC202201<br>* Atorvastatin Calcium Trihydrate<br>|
| Experimental: Cohort 3<br>Treatment B: DWP14012 40 mg qd for 7 days, followed by DWC202201 40 mg qd + DWP14012 40 mg qd for 7 days Treatment C: DWP14012 40 mg qd for 14 days Treatment A: DWC202201 40 mg qd for 7 days | Drug: DWP14012<br>* Potassium-competitive acid blocker<br>Drug: DWC202201<br>* Atorvastatin Calcium Trihydrate<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Atorvastatin Peak Plasma Concentration at steady state (Cmax,ss) after DWC202201 multiple dosing |  | [Time Frame: up to 64 days] | 
| Atorvastatin Area under the plasma concentration versus time curve at steady state (AUCinf, ss) after DWC202201 multiple dosing |  | [Time Frame: up to 64 days] | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Atorvastatin Area under the plasma concentration extrapolated to infinity at steady state (AUC,ss) after DWC202201 multiple dosing |  | [Time Frame: up to 64 days] | 
| Atorvastatin Time to peak drug concentration at staedy state (Tmax, ss) after DWC202201 multiple dosing |  | [Time Frame: up to 64 days] | 
| Atorvastatin Terminal Half-life at steady state (T1/2,ss) after DWC202201 multiple dosing |  | [Time Frame: up to 64 days] | 
| Atorvastatin Apparent total body clearance at steady state (CLss/F) after DWC202201 multiple dosing |  | [Time Frame: up to 64 days] | 
| Atorvastatin Apparent volume of distribution at steady state (Vd,ss/F) after DWC202201 multiple dosing |  | [Time Frame: up to 64 days] | 
| Atorvastatin active metabolite Area under the plasma concentration versus time curve at steady state (AUCinf, ss) after DWC202201 multiple dosing |  | [Time Frame: up to 64 days] | 
| Atorvastatin active metabolite Terminal Half-life at steady state (T1/2,ss) after DWC202201 multiple dosing |  | [Time Frame: up to 64 days] | 
| Atorvastatin active metabolite An estimate of the total body clearance at steady state (CL ss/F) after DWC202201 multiple dosing |  | [Time Frame: up to 64 days] | 
| Atorvastatin active metabolite Apparent volume of distribution at steady state (Vd,ss/F) after DWC202201 multiple dosing |  | [Time Frame: up to 64 days] | 
| Atorvastatin active metabolite metabolic ratio after DWC202201 multiple dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan Peak Plasma Concentration (Cmax) after DWP14012 single dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan Area under the plasma drug concentration-time curve from 0 to tau (AUCtau) after DWP14012 single dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan Area under the plasma drug concentration-time curve from 0 to infinity(AUCinf) after DWP14012 single dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan The time of peak concentration (Tmax) after DWP14012 single dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan Terminal Half-life (t1/2) after DWP14012 single dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan Apparent Clearance (CL/F) after DWP14012 single dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan Apparent Volume of Distribution After extravascular administration (Vd/F) after DWP14012 single dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan Peak Plasma Concentration at steady state (Cmax,ss) after DWP14012 multiple dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan Area under the plasma drug concentration-time curve from 0 to tau at steady state (AUCtau,ss) after DWP14012 multiple dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan Area under the plasma drug concentration-time curve from 0 to infinity at steady state (AUCinf,ss) after DWP14012 multiple dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan Time of Maximum Concentration at steady state (Tmax,ss) after DWP14012 multiple dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan Terminal Half-life at steady state (t1/2,ss) after DWP14012 multiple dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan An estimate of the total body clearance at steady state (CL ss/F) after DWP14012 multiple dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan Aapparent volume of distribution after extravascular administration at steady state (Vd,ss/F) after DWP14012 multiple dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan Accumulation ratio after DWP14012 multiple dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan active metabolite Peak Plasma Concentration (Cmax) after single dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan active metabolite Area under the plasma drug concentration-time curve from 0 to tau (AUCtau) after single dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan active metabolite Area under the plasma concentration extrapolated to infinity (AUCinf) after single dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan active metabolite The time of peak concentration (Tmax) after single dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan active metabolite metabolic ratio after single dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan active metabolite Peak Plasma Concentration at steady state (Cmax,ss) after multiple dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan active metabolite AUCtau,ss AUCinf,ss Tmax,ss metabolic ratio |  | [Time Frame: up to 64 days] | 
| Fexuprazan active metabolite Area under the plasma drug concentration-time curve from 0 to tau at steady state (AUCtau,ss) after multiple dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan active metabolite Area under the plasma concentration extrapolated to infinity at steady state (AUCinf,ss) after multiple dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan active metabolite The time of peak concentration at steady state (Tmax,ss) after multiple dosing |  | [Time Frame: up to 64 days] | 
| Fexuprazan active metabolite metabolic ratio after multiple dosing |  | [Time Frame: up to 64 days] |